Home › Endometrial Cancer › Alabama › Mobile
Endometrial Cancer clinical trials in Mobile, AL
4 studies for Endometrial Cancer are looking for participants at sites in and around Mobile (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
RecruitingPhase 2
- University of South Alabama Mitchell Cancer Institute, Mobile
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
RecruitingPhase 3
- University of South Alabama, Mitchell Cancer Institute ( Site 6033), Mobile
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
RecruitingPhase 3
- USAH Mitchell Cancer Inst, Mobile
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Mobile
Endometrial Cancer trials in other cities
- Houston, TX68 studies
- New York City, NY52 studies
- Boston, MA50 studies
- Arlington, VA39 studies
- Nashville, TN38 studies
- Los Angeles, CA34 studies
- St. Louis, MO29 studies
- Philadelphia, PA28 studies
- San Antonio, TX27 studies
- Queens, NY25 studies
- Columbus, OH25 studies
- Chicago, IL25 studies
Other studies in Mobile
- Non-Small Cell Lung Cancer13 studies
- Heart Failure13 studies
- Lung Cancer7 studies
- Breast Cancer7 studies
- Ovarian Cancer7 studies
- Obesity7 studies
- Cancer (all types)6 studies
- Melanoma6 studies
- Small Cell Lung Cancer6 studies
- Cardiovascular Disease6 studies
- Atrial Fibrillation5 studies
- Overweight5 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.